Miami, Fla., May 06, 2020 (GLOBE NEWSWIRE) -- The Diabetes Research Institute Foundation (DRIF) today announced a donation of $3 million from North Americas Building Trades Unions (NABTU), to support specific and urgent research on the use of umbilical cord mesenchymal stem cells to treat COVID-19-related inflammation. The generous gift will accelerate needed clinical trials during this challenging time. On April 5, 2020, the U.S.
Stem cells havent exactly panned out as hoped when it comes to approved therapeutics. There are only a couple that have received a nod from the FDA in very specific indications. But the ongoing COVID-19 pandemic could push stem cells back into the limelight and more firmly establish them as therapeutically relevant.
INTRODUCTION In the development of stem cell-based therapeutic platforms for tissue regeneration, the selection of which type of stem cell to use will be enormously important. Adult mesenchymal stem cells (MSCs) are considered one of the most promising tools for cell and cell-based gene therapy in bone repair (Gafni et al., 2004). Adult MSCs have been shown to possess the potential to differentiate into several lineages including bone, cartilage, fat, tendon, muscle, and marrow stroma (Haynesworth et al., 1992; Mackay et al., 1998; Yoo et al., 1998; Young et al., 1998; reviewed by Caplan and Bruder, 2001).
Introduction Mesenchymal stem cells (MSCs) were originally isolated from bone marrow (Friedenstein et al., 1968) but have since been detected in many tissues including dental pulp (Gronthos et al., 2002), adipose tissue (Zuk et al., 2002), and umbilical cord blood (Wang et al., 2004). The essential features of this heterogeneous cell population as defined by the International Society for Cellular Therapy (ISCT) in 2006 are adherence to plastic under culture conditions; expression of the cell surface markers CD44, CD90, CD105, and CD73; absence of the hematopoietic markers CD45, CD34, CD14, CD11b, CD79, CD19, and human leukocyte antigen-DR; and multi-differentiation potential, with the capacity to generate osteoblasts, chondroblasts, and adipocytes (Dominici et al., 2006). According to the recently published ISCT position statement, although the classic set of markers still applies to in vitro-expanded MSCs, surface markers are evolving (Viswanathan et al., 2019).
4 May 2020 A novel stem cell therapy may play a part in improving the survival rate of ventilator-dependent COVID-19 patients. Twelve COVID-19 patients at Mount Sinai Hospital in New York were treated with a new type of stem cell therapy, resulting ina survival rate of 83 percent, significantly higher than the 12 percent survival rate for similar untreated patients
SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced data from a recent animal study performed by the Company that demonstrate meaningful improvements in heart function for subjects treated with its allogenic (from another donor, or off the shelf) neurokinin 1 receptor positive mesenchymal stem cell (NK1R+ MSC) program for heart failure, known as CardiALLO. In addition, the Company is planning further exploration and discussion with the U.S
Mesenchymal Stem Cells: Stem cells are the basic building blocks of tissues and organs in the body. It is important to note that there is no single stem cell that gives rise to them but in fact a variety of them coming from different locations in the body and formed at different time periods.
Updated on 4/29 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.* Acalabrutinib (AstraZeneca): a selective inhibitor of Brutons tyrosine kinase (BTK) being investigated for the treatment of cytokine storm associated with COVID-19 in severely ill patients. BTK inhibition reduces the production of multiple cytokines and chemokines which may potentially reduce respiratory complications of COVID-19.
Market Study Report, LLC, has added a research study on ' Cell Freezing Media for Cell Therapy market' which offers a concise summary regarding market valuation, market share, regional spectrum, revenue estimation and SWOT analysis of this business vertical. The report further brings up key insights pertaining to growth opportunities and challenges to be experienced by key industry players, while emphasizing on their present competitive setting and growth plans for the ' Cell Freezing Media for Cell Therapy Market'
Abstract Heterotopic ossification (HO) in connective tissues like tendons and ligaments severely damages tissue structure. The pathogenesis of HO remains unclear but may involve mTOR.
Recent Comments